Biodexa Expands FAP Patient Support with Early Access Program and Roundtable Initiatives — Biodexa Pharmaceuticals PLC

Event summary

Biodexa held its first roundtable meeting in Paris on July 28, 2026, to expand support for FAP patients and clinicians.
The company has made eRapa available via an Early Access Program and Named Patient prescribing for FAP treatment.
eRapa is a proprietary oral capsule formulation of rapamycin, targeting mTOR over-expression in FAP polyps.
Biodexa's Phase 3 trial for eRapa is planned to enroll 168 patients across 30 clinical sites in the US and Europe.

The big picture

Biodexa's expansion of support for FAP patients aligns with broader industry trends toward patient-centric care and early access programs. The company's strategic focus on gastrointestinal cancers positions it within a competitive landscape where innovative treatments for rare diseases can command premium pricing. With a $20 million grant from the Cancer Prevention and Research Institute of Texas, Biodexa is well-funded to advance its clinical pipeline, but success will depend on executing its Phase 3 trial and securing regulatory approvals.

What we're watching

Clinical Trial Progress: The pace at which Biodexa can initiate and complete its Phase 3 trial for eRapa will determine the timeline for potential regulatory approval.
Market Expansion: Whether Biodexa can sustain its support activities for FAP patients while advancing multiple clinical programs simultaneously.
Regulatory Strategy: How Biodexa's pursuit of Orphan Drug Designation in Europe will impact its market positioning and competitive advantage.